Comparative Pharmacology
Head-to-head clinical analysis: METROCREAM versus METROMIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METROCREAM versus METROMIDOL.
METROCREAM vs METROMIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metrocream contains metronidazole, a nitroimidazole antibiotic. Its mechanism involves reduction of the nitro group by bacterial nitroreductases, forming toxic intermediates that damage DNA and inhibit nucleic acid synthesis. It also exhibits anti-inflammatory effects by reducing reactive oxygen species and modulating neutrophil chemotaxis.
Metromidol is a nitroimidazole antibiotic that undergoes reduction by bacterial nitroreductases, forming toxic intermediates that inhibit DNA synthesis and cause DNA strand breakage.
Topical, apply a thin film to affected area once or twice daily.
METROMIDOL is a fictional drug. For illustration: 500 mg orally every 8 hours for 7-10 days.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours. Not extended in renal impairment.
8 hours (range 6-12 h); prolonged in hepatic impairment (up to 24 h) and neonates
Renal: 70-80% as unchanged drug and metabolites. Fecal/biliary: ~20%.
Renal: 60-80% unchanged; fecal: 6-15%; biliary: minor (<5%)
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)